Suppr超能文献

轻离子放射治疗的最新进展。

Recent advances in light ion radiation therapy.

作者信息

Brahme Anders

机构信息

Department of Medical Radiation Physics, Karolinska Institute and Hospital, Box 260, SE-171 76 Stockholm, Sweden.

出版信息

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):603-16. doi: 10.1016/j.ijrobp.2003.09.034.

Abstract

BACKGROUND

The fast development of energy- and intensity-modulated radiation therapy during the last two decades using photon and electron beams has when implemented resulted in a considerable improvement of radiation therapy, particularly if combined with radiobiologically based treatment optimization techniques. This has made intensity-modulated electron and photon beams as powerful as today's uniform dose proton therapy. To be able to cure also the most advanced hypoxic and radiation-resistant tumors of complex local spread, intensity-modulated light ion beams are really the ultimate tool and in clinical practice 2 to 3 times less expensive per patient treated than proton therapy. This development and the recent development of advanced tumor diagnostics based on PET-CT imaging of the tumor cell density open the field for new powerful radiobiologically based treatment optimization methods. The ultimate step is to use the unique radiobiologic and dose distributional advantages of light ion beams for truly optimized bioeffect planning where the integral three-dimensional dose delivery and tumor cell survival can be monitored by PET-CT imaging and corrected by biologically based adaptive therapy optimization methods.

PURPOSE

The main purpose of the present paper is to discuss the principal areas of development of therapy optimization, by considering the therapy chain from tumor diagnostics and the use of three-dimensional predictive assay to biologically based treatment optimization with special focus on the rapid clinical development of advanced light ion therapy.

METHODS

Besides the "classical" approaches using low ionization density hydrogen ions (protons, but also possibly deuterons and tritium nuclei) and high ionization density carbon ions, two new approaches will be discussed. In the first one, lithium or beryllium or boron ions, which induce the least detrimental biologic effect to normal tissues for a given biologic effect in a small volume of the tumor, will be key particles. In the second approach, referred patients will be given a high-dose, high-precision "boost" treatment with carbon or oxygen ions during 1 week preceding the final treatment with conventional radiation in the referring hospital. The rationale behind these approaches is to minimize the high ionization density dose to the normal-tissue stroma outside but sometimes also inside the tumor bed and to ensure a more uniform and optimal biologic effectiveness in the tumor, also on the microscopic scale. The present discussion indicates that BIologically Optimized predictive Assay based light ion Radiation Therapy (Bio-Art) is really the ultimate way to perform high-precision radiation therapy using checkpoints of the integral dose delivery and the tumor response and, based on this information, perform compensating corrections of the dose delivery. By using biologically optimized scanned high-energy photon or ion beams, it is possible to measure in vivo the three-dimensional dose delivery using the same PET-CT camera that was used for diagnosing the tumor spread. This method thus opens up the door for truly three-dimensional biologically optimized adaptive radiation therapy, where the measured dose delivery to the true target tissues can be used to fine-adjust the incoming beams, so that possible errors in the integral therapy process are eliminated toward the end of the treatment. Interestingly enough, practically all major error sources--such as organ motion, treatment planning errors, patient setup errors, and dose delivery problems due to gantry, multileaf, or scanning beam errors--can be corrected for in this way.

RESULTS AND CONCLUSIONS

Radiobiologically optimized dose delivery using intensity and radiation quality modulation based on high-resolution PET-CT or Magnetic Resonance Spectroscopic Imaging (MRSI)-based tumor and normal-tissue imaging is probably the ultimate development of radiation therapy, taking the unique physical and biologic advantages of light ions fully into account in truly patient-individualized curative treatment schedules. Using recently available biologically based treatment ilable biologically based treatment optimization algorithms, it is possible to improve the treatment outcome for advanced tumors by as much as 10-40%. The adaptive radiotherapy process based both on three-dimensional tumor cell survival and dose delivery monitoring has the potential of percent accuracy in tumor response and dose delivery monitoring, using two-dimensional, narrow high-energy photon beam scanning and three-dimensional (11)C Bragg peak scanning for radiation quality and intensity-modulated dose delivery. There is no doubt that the future of radiation therapy is very promising, and gradually more and more patients may not even need advanced surgery. Instead, they could be cured by biologically optimized electron, photon, or light ion therapy, where the densely ionizing Bragg peak is placed solely in the gross tumor, and a lower ionization density is used in microscopically invasive tumor volumes.

摘要

背景

在过去二十年中,利用光子和电子束的能量及强度调制放射治疗发展迅速,应用后显著改善了放射治疗效果,特别是与基于放射生物学的治疗优化技术相结合时。这使得强度调制电子束和光子束的效能与当今的均匀剂量质子治疗相当。为了能够治愈局部扩散复杂的最晚期缺氧和抗辐射肿瘤,强度调制轻离子束确实是终极工具,并且在临床实践中,每位接受治疗的患者的费用比质子治疗低2至3倍。这一发展以及基于肿瘤细胞密度的PET-CT成像的先进肿瘤诊断技术的最新进展,为基于放射生物学的新的强大治疗优化方法开辟了领域。最终步骤是利用轻离子束独特的放射生物学和剂量分布优势进行真正优化的生物效应规划,其中三维剂量输送和肿瘤细胞存活可通过PET-CT成像进行监测,并通过基于生物学的自适应治疗优化方法进行校正。

目的

本文的主要目的是通过考虑从肿瘤诊断到三维预测分析的治疗链,再到基于生物学的治疗优化,特别关注先进轻离子治疗的快速临床发展,来讨论治疗优化的主要发展领域。

方法

除了使用低电离密度氢离子(质子,也可能是氘核和氚核)和高电离密度碳离子的“经典”方法外,还将讨论两种新方法。在第一种方法中,锂、铍或硼离子将成为关键粒子,对于肿瘤小体积内给定的生物效应,它们对正常组织产生的有害生物效应最小。在第二种方法中,转诊患者将在转诊医院接受常规放疗的最后治疗前1周,用碳或氧离子进行高剂量、高精度的“增强”治疗。这些方法背后的基本原理是将高电离密度剂量降至肿瘤床外部但有时也包括内部的正常组织基质,并确保肿瘤内更均匀和最佳的生物有效性,即使在微观尺度上也是如此。目前的讨论表明,基于生物学优化预测分析的轻离子放射治疗(Bio-Art)确实是使用积分剂量输送和肿瘤反应检查点进行高精度放射治疗的终极方法,并基于此信息对剂量输送进行补偿校正。通过使用生物学优化的扫描高能光子或离子束,可以使用用于诊断肿瘤扩散的同一台PET-CT相机在体内测量三维剂量输送。因此,这种方法为真正的三维生物学优化自适应放射治疗打开了大门,其中测量到的向真正靶组织的剂量输送可用于微调入射束,从而在治疗结束时消除积分治疗过程中可能出现的误差。有趣的是,几乎所有主要误差源——如器官运动、治疗计划误差、患者摆位误差以及由于机架、多叶或扫描束误差导致的剂量输送问题——都可以通过这种方式得到校正。

结果与结论

基于高分辨率PET-CT或基于磁共振波谱成像(MRSI)的肿瘤和正常组织成像,利用强度和辐射质量调制进行放射生物学优化的剂量输送,可能是放射治疗的最终发展方向,在真正针对患者个体化的治愈性治疗方案中充分考虑了轻离子独特的物理和生物学优势。使用最近可用的基于生物学的治疗优化算法,有可能将晚期肿瘤的治疗效果提高10%至40%。基于三维肿瘤细胞存活和剂量输送监测的自适应放射治疗过程,在肿瘤反应和剂量输送监测方面具有潜在的百分比精度,采用二维窄高能光子束扫描和三维(11)C布拉格峰扫描进行辐射质量和强度调制剂量输送。毫无疑问,放射治疗的未来非常有前景,越来越多的患者甚至可能不再需要先进的手术。相反,他们可以通过生物学优化的电子、光子或轻离子治疗治愈,其中密集电离的布拉格峰仅置于大体肿瘤中,而在微观侵袭性肿瘤体积中使用较低的电离密度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验